SCHEMBL4186859

SCHEMBL4186859

CNS(=O)(=O)CCc1ccc(N)c(Br)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
PTGES2 Q9H7Z7 12/20 0.41
HTR1A P08908 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
MMP8 P22894 3/20 0.36
MMP12 P39900 3/20 0.36
MMP13 P45452 3/20 0.36
MMP1 P03956 2/20 0.36
MMP7 P09237 2/20 0.36
SKP2 Q13309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15292050 0.86 SKP2 (0.51) PTGES2HTR1AHTR1DHTR1BMMP8
Dimethylamine SCHEMBL17667849 0.84 CA12 (0.42) CA12CA1CA2CA4CA6
SCHEMBL7612991 0.84 CA1 (0.44) CA12CA1CA2CA4CA6
SCHEMBL3081433 0.84 PTGES2 (0.44) CA12CA1CA2CA4CA6
SCHEMBL12017198 0.81 CYP3A4 (0.53) CA12CA1CA2CA4CA6
SCHEMBL1275294 0.81 CA12 (0.41) CA12CA1CA2CA4CA6
SCHEMBL4187997 0.78 CA2 (0.42) CA12CA1CA2CA4CA6
SCHEMBL1275321 0.76 RECQL (0.58) CA12CA1CA2CA6CA5A
Hydrochloric Acid SCHEMBL4731092 0.75 RECQL (0.61) CA12CA1CA2CA6CA5A
SCHEMBL23732878 0.74 TAAR1 (0.57) CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452996-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-09-27 US disclosed
US-9452996-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-09-27 US disclosed
EP-2021329-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-04-13 EP disclosed
US-20160046602-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-02-18 US disclosed
US-20160046602-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-02-18 US disclosed
US-9221797-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2015-12-29 US disclosed
US-9221797-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2015-12-29 US disclosed
US-20140148448-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed
US-20140148448-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed
US-8674100-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2014-03-18 US disclosed
US-8674100-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2014-03-18 US disclosed
US-8674100-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2014-03-18 US disclosed
EP-2687516-A1 Inhibitors of C-FMS Kinase Janssen Pharmaceutica N.V. (BE) 2014-01-22 EP disclosed
EP-2021329-A1 INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica, N.V. (BE) 2009-02-11 EP disclosed
WO-2007124318-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
US-20070249649-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed
US-20070249649-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed
US-20070249649-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249649-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CA12 1317/4885CA1 346/4885CA2 637/4885
US-20140148448-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CA12 1317/4885CA1 346/4885CA2 637/4885
US-20160046602-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CA12 1317/4885CA1 346/4885CA2 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.